Company Info / Access

Business	PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners.
Establishment	July 2006
Representative Director, President, Chief Executive Officer (CEO)	Patrick C. Reid
Number of Employees (Consolidated)	751 (As of December 31, 2025)
URL	https://www.peptidream.com/en/
Address	〒210-0821 3-25-23 Tonomachi, Kawasaki-ku, Kawasaki City, Kanagawa Prefecture. TEL +81-44-270-1300
Access	By Train Take the Keikyu Daishi Line from Keikyu Kawasaki Station to Kojima Shinden Station, approximately 20 minutes by foot Approximately 18 minutes by foot from Haneda Airport Terminal 3 Station, the Keikyu Airport Line By Taxi Approximately 20 minutes from Kawasaki and Kamata Stations By Bus From Kawasaki station(JR・Keikyu Line) by Rinko Bus Bus Line "Kawa 03 (Ukishima Bus Terminal-bound) ", from Kawasaki Station to KING SKYFRONT Entrance , 8 minutes by foot Rapid Express Bus(Ukishimabashi-bound), from Kawasaki Station to KING SKYFRONT Entrance , 8 minutes by foot Bus Line "Kawa 02(King Skyfront East)", from Kawasaki Station to Tonomachi, KING SKYFRONT East , 1 minutes by foot From Tenkubashi Station(Tokyo Monorail・Keikyu Airport Line) by Rinko Bus Bus Line "Dai 109(Daishi-bashi mae)", from Tenkubashi Station to KING SKYFRONT East, 1 minutes by foot From Haneda Airport Terminal 3 Station (Tokyo Monorail・Keikyu Airport Line) by Rinko Bus Bus Line "Sora 84(Daishi-bashi mae)", from Haneda Airport Terminal 3 Station to KING SKYFRONT East, 1 minutes by foot * Operating hours: 10:00 ~ 17:00 By Car Approximately 5 minutes from Metropolitan Expressway Airport-west IC Approximately 5 minutes from Metropolitan Expressway Daishi IC Approximately 5 minutes from Metropolitan Expressway Tonomachi IC
PeptiDream Equity Shareholdings	PDRadiopharma Inc.（100％ equity stake and consolidated subsidiary） Business：Research, development, manufacturing, sales, export and import of radiopharmaceuticals and related products PeptiGrowth Inc.（39.5％ equity stake and affiliated company） Business：Development, production and marketing of peptides to replace existing growths, key ingredients of cell culture medium. PeptiAID Inc （39.4％ equity stake and affiliated company） Business：Research, development, manufacturing, sales, export and import of pharmaceutical products PeptiStar Inc.（less than 20％ equity stake） Business：Contract Development and Manufacturing Organization (“CDMO”) for the research and commercial manufacture of peptide therapeutics LinqMed Inc.（less than 15％ equity stake） Business：Development of radiopharmaceuticals 　　　　　　　　　　　　　　　　　 Alivexis, Inc.（less than 5％ equity stake） Business：pursuing a technology and computational-driven approach to drug discovery